



Reply Pursuant to 37 C.F.R. § 1.116
Expedited Procedure
Group Art Unit 1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF
RIETHMULLER-WINZEN *et al.*

Group Art Unit: 1617

Examiner: S. HUI

Appln. No.: 09/666,146

Filed: September 20, 2000

Title: METHOD FOR THE THERAPEUTIC MANAGEMENT OF EXTRAUTERINE
PROLIFERATION OF ENDOMETRIAL TISSUE, CHRONIC PELVIC PAIN AND
FALLOPIAN TUBE OBSTRUCTION

10/04/2002 SSITHIB1 00000073 033975 09666146
02-FC:117 920.00 CH

October 3, 2002

* * * * *

AMENDMENT PURSUANT TO 37 C.F.R. § 1.116

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

This is in response to the official action dated April 4, 2002, wherein the pending claims were rejected under 35 U.S.C. § 103(a). The applicants respectfully traverse in view of the following amendment and remarks.

I. AMENDMENT

Prior to further action on the merits, please amend the application as follows.

IN THE CLAIMS

Please amend claim 2 as follows.

2. (Twice Amended) In the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction, the improvement consisting of administration of an LHRH antagonist in the form of a short term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, wherein the LHRH antagonist is administered in a dosage to achieve the estrogen serum